Company news
Aditxt, Inc. news in 2023
Aditxt, Inc.'s news releases, calls and decks from 2023, newest first.
Aditxt Announces $6 Million Private Placement Priced At-The-Market under Nasdaq Rules
December 28, 2023
Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally
December 11, 2023
Aditxt, Inc. Announces Appointment of Ernie Lee as CEO of its Wholly-Owned Subsidiary, Pearsanta, to Lead Launch of Test2Treat.me Platform
October 4, 2023
Aditxt Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
August 30, 2023
Aditxt, Inc. (NASDAQ: ADTX) Provides Shareholder Update and Planned Strategy for Achieving Commercial Scale
August 17, 2023
CORRECTING and REPLACING Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on August 18, 2023
August 16, 2023
Aditxt Subsidiary Adimune Signs Clinical Trial Agreement with Top Research Institution to Study Stiff Person Syndrome
May 4, 2023
Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid – with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan
April 19, 2023
Aditxt Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
April 19, 2023
Aditxt Issues Shareholder Update
April 16, 2023
Aditxt Names Media Industry Veteran Maureen Connolly as Chief Content and Engagement Officer
March 7, 2023
Aditxt Retains Riverside Management Group as Advisor to Support Strategic M&A Driven Acquisitions by Subsidiary Pearsanta, Inc.
March 2, 2023
Aditxt Forms its Second Subsidiary, Pearsanta, Inc., to Accelerate the Growth of its AditxtScore™ Program and Appoints Healthcare Executive and Current Head of AditxtScore™ Anthony Voorhies to Serve as its President
February 13, 2023
Aditxt Forms Adimune, Inc. as a Wholly Owned Subsidiary with a Focus on Immune Modulation Therapies and Appoints Dr. Friedrich Kapp, Former President of the Therapeutic Business Unit at Schering AG, as its Chairman and CEO
January 2, 2023